Patients with structural heart disease are at risk for life-threatening ventricular tachycardias (VTs). Implantable cardioverter-defibrillators (ICDs) can terminate VT, but often at the cost of ...

Catheter ablation guided by electroanatomic mapping is now a viable treatment option to reduce episodes of recurrent ventricular tachycardia (VT) in patients who have experienced myocardial infarction ...

The first randomized trial to investigate preventive ablation of a potential arrhythmogenic substrate associated with coronary chronic total occlusion (CTO) in patients at high risk of ventricular ...

SAN DIEGO--(BUSINESS WIRE)--Vektor Medical, a medical technology company transforming cardiac arrhythmia care, today announced the publication of a peer-reviewed study in EP Europace evaluating ...

Baltimore, MD - A report published this week has shown a high rate of ventricular tachycardia (VT) recurrence—as high as 75% at 14 months—in arrhythmogenic right ventricular dysplasia/cardiomyopathy ...

WALTHAM, Mass.--(BUSINESS WIRE)--Thermedical ®, a developer of thermal-ablation systems to treat ventricular arrhythmias, announced today that the U.S. Food & Drug Administration (FDA) has approved an ...

Loyola Medicine is among two centers in the world offering a novel catheter ablation system intended to improve treatment outcomes for a life-threatening heart rhythm disorder called ventricular ...

A technique borrowed from radiation oncology that takes the catheter out of catheter ablation continued to put in an impressive performance, observers say, in the longest yet follow-up of patients ...

Ablation, a procedure to treat abnormal electrical short circuits caused by a heart attack and is usually reserved for patients who do not improve with medication, may be a better first-line treatment ...

Ventricular tachycardia (VT) is caused by abnormal electrical circuits originating from diseased areas of the ventricular myocardium. It usually results in a rapid heartbeat, preventing effective ...

BERLIN, Germany—Performing ventricular tachycardia (VT) ablation before placement of a primary prevention implantable cardioverter-defibrillator (ICD) had a clinical benefit in a selected group of ...

NEW ORLEANS – The Impella 5.0 and 5.5 left ventricular assist device failed to measure up on outcomes when used for high-risk patients undergoing ventricular tachycardia (VT) ablation therapies, ...